evipedia.ai
← Back

Griffonia simplicifolia for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: 5-HTP, 5-Hydroxytryptophan, L-5-Hydroxytryptophan, Oxitriptan, Griffonia Seed Extract, Bandeiraea simplicifolia

Motivation

Griffonia simplicifolia is a woody climbing shrub of the West African forest belt whose black seeds are unusually rich in 5-hydroxytryptophan, or 5-HTP — the molecule the body converts in a single step into serotonin. Because serotonin helps set mood, appetite and the timing of sleep, seed extracts have become one of the most widely sold plant-derived supplements aimed at those three targets.

In West Africa the plant was long used for chewing sticks, animal fodder and as an insecticide, and it entered world trade only after the serotonin pathway was mapped in the mid-twentieth century. Ghana alone has exported thousands of tonnes of seed, and China is now the main buyer and processor. Views on the extract range from treating it as a gentle plant alternative to prescription mood medication to dismissing it as a leftover of an older, contested model of low mood.

This review examines what controlled human research shows about Griffonia simplicifolia and the 5-HTP it supplies: which effects have been measured, how large those effects are, what the safety record actually contains, and where the evidence remains thin or contested.

Benefits - Risks - Protocol - Conclusion

High-level overviews of Griffonia simplicifolia, its 5-HTP content and the practice of loading the serotonin pathway with a precursor, drawn from expert platforms and narrative scientific literature.

A note on the priority platforms: two of the six carry nothing that qualifies. A direct on-site search of peterattiamd.com for “5-HTP” returned “Nothing Found — No results”, and lifespan.io returned “No Articles Found.” for the same term. FoundMyFitness surfaces 5-HTP only as brief asides inside podcast episodes devoted to unrelated subjects, which does not meet the depth bar applied here; the three remaining priority platforms are represented above.

Grokipedia

Griffonia simplicifolia

A single reference entry covering the plant’s botany and West African range, its seed chemistry, the 5-HTP extraction trade, and the clinical claims made for the extract, with citations to primary literature.

Examine

Griffonia simplicifolia

Dedicated entry on the shrub itself: its standing as the largest natural source of 5-HTP, seed content of up to 20% by weight, and human doses extrapolated from rodent work.

ConsumerLab

L-Tryptophan and 5-Hydroxytryptophan (5-HTP) Supplements Review

Independent laboratory testing of 5-HTP and L-tryptophan products for label accuracy and impurities, with top picks, dose guidance by intended use, and a running log of contamination and interaction warnings.

Systematic Reviews

Systematic reviews and meta-analyses indexed on PubMed that bear on Griffonia simplicifolia through its active constituent, 5-HTP.

Trade-off coverage: the principal claimed effect (mood) and the principal risk (excess serotonin signalling) are each represented above. No systematic review or meta-analysis exists for the appetite, sleep, pain or cognitive claims made for this extract, so those rest on individual trials described in later sections.

Mechanism of Action

Griffonia simplicifolia seeds carry 6–20% 5-HTP by wet weight, and that molecule carries essentially all of the extract’s activity. The body normally makes 5-HTP from dietary tryptophan using tryptophan hydroxylase (the rate-limiting enzyme that adds a hydroxyl group to tryptophan). Supplying it directly bypasses that bottleneck and the transporter competition tryptophan faces at the blood-brain barrier. Aromatic L-amino acid decarboxylase (the enzyme that removes a carboxyl group to finish the job) then converts 5-HTP into serotonin, a portion of which is processed onward into melatonin. Serotonin is cleared by monoamine oxidase (the enzyme that breaks down serotonin and related transmitters) to 5-hydroxyindoleacetic acid (5-HIAA), the inactive by-product measured in urine.

5-HTP has no receptor selectivity of its own, raising serotonin non-selectively at every subtype, from the 5-HT1A receptor tied to mood and anxiety to the 5-HT2B receptor found on heart valves. Oral bioavailability is roughly 50–70%, peak blood levels arrive 1.5–3 hours after a dose, and the plasma half-life is short at about 2 hours, hence divided or sustained-release dosing. Elimination is enzymatic; 5-HTP is not a meaningful substrate for the cytochrome P450 (CYP) enzymes that metabolise most oral medication.

The mechanistic dispute concerns location. Decarboxylase is abundant in gut, liver, kidney and blood vessels, so critics argue most of an oral dose becomes peripheral serotonin that cannot re-enter the brain — the reason older trials added carbidopa, a peripheral decarboxylase inhibitor. Defenders point to measurable central effects without carbidopa, and to peripheral serotonin driving part of the appetite response.

Historical Context & Evolution

The plant’s original documented uses had nothing to do with the brain. In Ghana, Côte d’Ivoire and Togo, Griffonia simplicifolia served as chewing sticks, wound dressings, livestock fodder, a dye source and an insecticide, and its seed proteins later became standard laboratory stains for blood vessels and nerve cells. Interest followed the mapping of the serotonin pathway in the 1950s: once 5-HTP was identified as serotonin’s immediate precursor, neurologists trialled it for involuntary muscle jerking, hereditary ataxias and low mood, and the seed was recognised in the 1970s as by far the cheapest natural source of the compound.

Two events shaped its modern position. First, the 1989 outbreak of eosinophilia-myalgia syndrome — a disabling illness of severe muscle pain with a raised count of one type of white blood cell — was traced to contaminated L-tryptophan from a single manufacturer. Tryptophan left the market and 5-HTP inherited its customers. Suspicion transferred with the customers: a trace impurity signal nicknamed “peak X” was reported in some 5-HTP samples, and cases of the syndrome were later described in 5-HTP users. Analytical work has since argued the peak was largely an artefact at vanishing concentrations, though that reassurance came from an industry-affiliated laboratory and the case reports were never formally retracted. Second, the serotonin-deficiency account of low mood came under sustained challenge in the 2020s, which reframed rather than removed the rationale for precursor loading. Recent trials have shifted focus to sleep, cognition and pain in older adults.

Expected Benefits

Medium 🟩 🟩

Reduced Depressive Symptoms ⚠️ Conflicted

Supplemental 5-HTP raises serotonin availability, the mechanism most antidepressants target from a different angle. A 2020 meta-analysis of 13 investigations found a pooled remission rate of 0.65 and a large effect on symptom questionnaires, while explicitly rating the trials weak and largely placebo-free. The Cochrane review reached the same direction from a far smaller base: only 2 of 108 candidate trials survived quality screening. Evidence is therefore consistently positive but consistently fragile, and the underlying serotonin-deficiency premise is itself contested.

Magnitude: Pooled remission rate 0.65 (95% confidence interval, or CI, 0.55–0.78) across 13 investigations, with a standardised effect size of 1.11 on symptom questionnaires (95% CI 0.53–1.69); the two adequately controlled trials pooled by the Cochrane systematic review gave an odds ratio of 4.10 (the ratio of improvement odds between groups; 95% CI 1.28–13.15) across 64 participants (Javelle et al., 2020).

Reduced Appetite and Modest Weight Loss

Serotonin signalling promotes early satiety and specifically suppresses carbohydrate intake, and this is the most reproducible clinical finding for 5-HTP. Three double-blind trials from the same Rome group showed reduced energy intake, earlier satiety and weight loss in obese adults at 750–900 mg daily, with and without a prescribed diet, including in overweight patients with type 2 diabetes. A later Italian trial using a Griffonia extract oral spray confirmed absorption by urinary metabolite rise and reported reduced hunger scores and body mass index.

Magnitude: Direction is consistent — lower daily energy intake, reduced carbohydrate selection, earlier satiety and weight loss at 750–900 mg daily over 5–12 weeks in obese adults; the trials report group-level significance rather than a pooled effect size, so the literature provides no single outcome figure (Cangiano et al., 1992; Ceci et al., 1989; Cangiano et al., 1998; Rondanelli et al., 2012).

Low 🟩

Improved Sleep Quality in Poor Sleepers

A 12-week randomised controlled trial (RCT, a study allocating participants by chance) in adults aged around 66 found 100 mg daily improved subjective sleep scores in poor sleepers, but not in those already sleeping well. Blood serotonin rose in parallel, supporting a pathway effect rather than chance.

Magnitude: Global sleep score fell by 2.80 ± 1.10 points in poor sleepers at week 12 (p = 0.005) in a 30-participant trial with no placebo arm (Sutanto et al., 2024).

Reduced Migraine Attack Intensity and Duration

Serotonin depletion is one classical model of migraine, and 5-HTP was tested against an established preventive drug rather than placebo. Benefit fell mainly on attack intensity and duration rather than frequency, with fewer adverse effects than the comparator; the absent placebo arm is the central limitation.

Magnitude: 71% of patients improved on 5-HTP versus 75% on methysergide across 124 randomised migraineurs (Titus et al., 1986).

Fibromyalgia Symptom Relief

A double-blind placebo-controlled trial in 50 patients reported significant improvement across every clinical parameter measured at 100 mg three times daily, sustained in a subsequent 90-day open extension. The trials are small, single-centre, decades old and never replicated.

Magnitude: All measured clinical parameters improved significantly versus placebo over 30 days in 50 patients; the report gives no effect size, so the literature supplies no outcome figure (Caruso et al., 1990).

Improved Cognitive Screening Scores in Older Adults

A 12-week trial in Singaporean adults around 66 found a small rise on a standard cognitive screen alongside increased blood serotonin, with no change in blood markers of amyloid protein. The trial was single-blinded, uncontrolled by placebo and very small.

Magnitude: Montreal Cognitive Assessment score rose from 26.6 ± 1.4 to 27.6 ± 1.4 points out of 30 over 12 weeks (p < 0.05, n = 30) (Li et al., 2025).

Reduced Anxiety and Panic Symptoms

Raised serotonin availability dampens panic circuitry, and 5-HTP has been tested against both placebo and an established antidepressant. Benefit is modest and confined to symptomatic populations: the recent older-adult trial found no change on an anxiety inventory. All the trials are small and none ran beyond a few weeks.

Magnitude: 200 mg cut subjective anxiety, panic symptom score and panic attack count versus placebo in 24 panic disorder patients, with no effect in 24 healthy controls (Schruers et al., 2002); a 45-patient double-blind trial found only moderate symptom reduction, below clomipramine (Kahn et al., 1987).

Speculative 🟨

Favourable Shifts in Gut Microbial Composition

The older-adult sleep trial reported increased microbial diversity and more short-chain fatty acid producers in poor sleepers. The basis is one small unblinded trial with no clinical endpoint attached to the change.

Antioxidant and Antimicrobial Activity of the Whole Seed Extract

Whole-seed extracts contain flavonoids and beta-carboline alkaloids beyond 5-HTP, and show antioxidant and antimicrobial activity in cell and rodent work. No controlled human study has tested whether these constituents contribute anything at supplement doses.

Benefit-Modifying Factors

  • Serotonin transporter and enzyme variants: carriers of the short 5-HTTLPR promoter variant of SLC6A4 (the gene encoding the protein that recycles serotonin) and low-activity TPH2 variants (the gene making the brain’s serotonin-building enzyme) plausibly respond differently, but no trial has stratified by genotype.
  • Baseline sleep and mood status: benefit concentrates in those starting badly. Sleep gains appeared only in poor sleepers, not in good sleepers, and appetite effects were largest in the most persistently hungry obese participants.
  • Baseline tryptophan availability: patients with type 2 diabetes had measurably reduced brain tryptophan availability at baseline and showed clear energy-intake reductions (Cangiano et al., 1998), suggesting a larger effect where the precursor supply is already constrained.
  • Sex differences: women predominate in the appetite and fibromyalgia trials and men in none of them, and brain serotonin synthesis rates differ by sex; whether response differs has never been tested directly, so this remains an open gap rather than a known modifier.
  • Age: the two most recent controlled trials were conducted specifically in adults aged 63–69 and found sleep and cognitive effects at only 100 mg daily, a quarter of the doses used in younger obese cohorts.
  • Pre-existing conditions: low stomach acid, coeliac disease or bariatric surgery reduce amino-acid absorption; carcinoid tumours (rare hormone-secreting tumours) already overproduce serotonin, which makes further loading pointless and hazardous.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Dose-Dependent Gastrointestinal Upset

Nausea is the single most frequently reported adverse effect, followed by vomiting, abdominal cramps, diarrhoea and constipation. The mechanism is peripheral: decarboxylase in the gut wall converts much of an oral dose to serotonin locally, and gut serotonin drives motility and the vomiting reflex. Severity tracks dose closely — it is common and often treatment-limiting at 750–900 mg daily but uncommon at 50–100 mg. Effects are reversible on dose reduction and typically abate over the first one to two weeks.

Magnitude: Mild transient adverse events in 2 of 18 healthy volunteers (11%) at 100 mg daily for 28 days; nausea becomes the dominant complaint at the 750–900 mg doses used in the obesity trials (Schlemmer et al., 2026).

Medium 🟥 🟥

Serotonin Syndrome When Combined with Serotonergic Agents

Serotonin syndrome is a potentially fatal reaction to serotonin excess, presenting as agitation, tremor, muscle rigidity, rapid heartbeat, sweating and high fever. 5-HTP alone has not been shown to cause it at supplement doses, but adding a precursor to any drug that raises serotonin is additive by design. A published case describes serotonin syndrome with rhabdomyolysis (breakdown of muscle tissue releasing damaging protein into the blood) in a man taking 5-HTP with sertraline. The risk is entirely avoidable by not combining agents.

Magnitude: Reported as isolated case reports rather than trial-derived rates, since no controlled trial has deliberately co-administered 5-HTP with a serotonin-raising drug in numbers sufficient to estimate an incidence; the direction is unambiguous — risk rises steeply with each additional serotonergic agent (Haberzettl et al., 2013).

Altered Sleep Architecture and Next-Day Grogginess

5-HTP shifts the timing and proportion of rapid eye movement (REM) sleep, the dreaming stage, and can compress deep sleep into the first part of the night. A recognisable pattern is rapid sleep onset followed by a wakeful stretch three to four hours later. Vivid dreaming and morning heaviness are common at higher evening doses. The effect is dose- and timing-dependent and reverses immediately on stopping.

Magnitude: A controlled sleep-laboratory study in Parkinson’s patients increased the proportion of REM sleep at 50 mg daily without a corresponding rise in arousal events; the literature reports no incidence figure for next-day grogginess because no trial has used it as an endpoint (Meloni et al., 2022).

Low 🟥

Eosinophilia-Myalgia Syndrome from Contaminated Material ⚠️ Conflicted

Eosinophilia-myalgia syndrome and isolated eosinophilia have been reported in a handful of 5-HTP users, with implicated batches carrying “peak X” impurities absent from unaffected samples. An industry-affiliated laboratory concluded the peak was an artefact at negligible concentration (Das et al., 2004). The case count stays tiny against decades of use.

Magnitude: One case of the syndrome and four of isolated eosinophilia across the two exposed groups in the only formal investigation; no denominator exists, so the literature reports no incidence rate (Michelson et al., 1994).

High oral and intravenous doses have produced confusion, anxiety and memory impairment in a dose-dependent pattern, and caution is standard in people with schizophrenia because serotonergic loading can aggravate psychotic symptoms. These effects are not seen at the 50–200 mg range used in recent trials.

Magnitude: Direction is dose-dependent, with reports concentrated at intravenous and high oral exposures well above supplement ranges; the literature reports no outcome figure because no dose-ranging trial has measured these endpoints systematically (Turner et al., 2006).

Speculative 🟨

Valvular Heart Changes from Sustained Peripheral Serotonin Exposure

Chronic 5-HT2B receptor stimulation causes heart valve fibrosis, the mechanism behind withdrawn appetite suppressants. Because most oral 5-HTP becomes peripheral serotonin, the theoretical concern applies, but no human case has been attributed to it.

Blunted Sexual Desire and Performance

Rodent work shows Griffonia seed extract impairs sexual behaviour in both sexes, matching the dysfunction seen with serotonin-raising drugs. No human trial has measured this, so the basis is animal data and class analogy.

Risk-Modifying Factors

  • Metabolising-enzyme variants: low-activity MAOA variants (the gene for the main serotonin-degrading enzyme) slow serotonin clearance and plausibly widen the margin for serotonergic excess; no clinical testing exists, so this is mechanistic reasoning rather than an established modifier.
  • Baseline urinary 5-HIAA: an already elevated 5-HIAA suggests high endogenous serotonin turnover, including undiagnosed carcinoid disease, and marks someone for whom further loading is inadvisable.
  • Sex differences: women report gastrointestinal adverse effects more often across serotonergic agents generally and made up most participants in the appetite trials; whether this reflects a true sex difference for 5-HTP has never been tested.
  • Pre-existing conditions: inflammatory bowel disease, gastroparesis (delayed stomach emptying) and reflux amplify the gut side effects; schizophrenia, bipolar disorder and carcinoid tumours each raise the consequences of serotonergic loading substantially.
  • Age: older adults carry more polypharmacy — the strongest predictor of an accidental serotonergic combination — and greater sensitivity to sedation and falls from a bedtime dose.
  • Concurrent antidepressant use: the dominant risk modifier by a wide margin, converting a low-risk supplement into a plausible serotonin syndrome trigger.

Key Interactions & Contraindications

  • Monoamine oxidase inhibitors (MAOIs, an older antidepressant class that blocks serotonin breakdown; phenelzine, tranylcypromine, selegiline, moclobemide): absolute contraindication. Blocked degradation plus added supply is the classic recipe for serotonin syndrome. Separation in time does not mitigate; a 14-day washout after stopping the MAOI is standard.
  • Selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors (SSRIs and SNRIs, antidepressants that keep serotonin in the synapse longer; fluoxetine, sertraline, escitalopram, venlafaxine, duloxetine): avoidance unless supervised. Additive serotonergic effect with reported serotonin syndrome and muscle breakdown; no dose separation removes the interaction.
  • Triptans and other migraine agents (sumatriptan, rizatriptan, zolmitriptan): caution. Both raise serotonin signalling, with additive risk of tremor, agitation and rapid heartbeat. Close monitoring is standard, and same-day use with high 5-HTP doses is avoided.
  • Tramadol, dextromethorphan, linezolid, methylene blue and fentanyl: caution to contraindication. Each raises serotonin by a distinct route; combinations have produced serotonin syndrome. A non-serotonergic analgesic or cough agent is the usual substitution where one exists.
  • Carbidopa and other peripheral decarboxylase inhibitors: monitor. Carbidopa sharply increases how much 5-HTP reaches the brain, amplifying both effect and risk; scleroderma-like skin reactions (progressive hardening and thickening of the skin) have been reported on the combination. Prescriber supervision only.
  • Over-the-counter serotonergic and sedating agents (dextromethorphan cough syrups, diphenhydramine, doxylamine, St John’s wort sold without prescription): caution. Additive sedation and, for St John’s wort, additive serotonergic load. Separation of at least four hours, or avoidance altogether, is the usual handling.
  • Supplements with additive serotonergic effect (St John’s wort, S-adenosylmethionine, L-tryptophan, tryptophan-rich protein powders, high-dose green tea extract): caution. Each raises serotonin availability or its delivery, compounding both benefit and syndrome risk; no published protocol stacks them.
  • Vitamin B6 (pyridoxine): monitor. Vitamin B6 is the cofactor for the decarboxylase step, so high-dose B6 accelerates peripheral conversion and can increase nausea while reducing brain delivery. Separating the two across the day is the standard workaround.
  • Other interventions: caution with psilocybin, other serotonergic psychedelics and lithium, all of which act on serotonin systems; and with alcohol, which compounds the sedation. Whole-body heat exposure and intense endurance exercise both raise serotonergic tone and may add to daytime drowsiness.

Populations who should avoid Griffonia simplicifolia:

  • Anyone taking an MAOI, SSRI, SNRI, tricyclic antidepressant, tramadol or linezolid
  • People with carcinoid tumours or any neuroendocrine tumour producing serotonin
  • People with schizophrenia or an active psychotic disorder, and those with bipolar disorder not on a mood stabiliser
  • Pregnant or breastfeeding women, on absence of any safety data rather than evidence of harm
  • People with Child-Pugh Class B or C liver impairment (moderate-to-severe liver failure) or an estimated glomerular filtration rate below 30 mL/min/1.73 m², in whom clearance of the amino acid and its metabolites is unstudied
  • People with a personal history of eosinophilia-myalgia syndrome or unexplained eosinophilia
  • People scheduled for surgery within two weeks, because of additive serotonergic effects with fentanyl and other anaesthetic agents

Risk Mitigation Strategies

  • Low starting dose with slow titration: protocols begin at 50 mg once daily for one week, then increase by 50 mg every 5–7 days to the target, which prevents the nausea and cramping that dominate at abrupt higher intakes.
  • Divided dosing with food: dividing anything above 100 mg into two or three doses taken with meals blunts the peak gut serotonin surge that drives nausea and vomiting.
  • Full serotonergic medication audit: checking all prescription, over-the-counter and supplement products against a serotonin-interaction checker before the first dose is the single measure that prevents serotonin syndrome.
  • Enteric-coated or sustained-release forms: these shift absorption past the upper small intestine, reducing local gut conversion and the nausea it causes, and flatten the peak that drives next-day grogginess.
  • Third-party purity testing: lots carrying a certificate of analysis covering the “peak X” impurity profile address the contamination pathway implicated in the eosinophilia-myalgia case reports.
  • Evening dose 60–90 minutes before bed for sleep use: a dose taken too close to lights-out concentrates the sleep-architecture shift into the early night, producing the three-hour wake-up pattern.
  • A 200 mg daily ceiling for chronic use: long-term intakes above this have no supporting trial data and increase sustained peripheral serotonin exposure, the theoretical basis of the heart-valve concern.
  • Eosinophil count at 3 months: a complete blood count with differential detects the eosinophil rise that precedes the muscle-pain syndrome, allowing discontinuation before symptoms develop.

Therapeutic Protocol

  • Standard mood protocol: 100–300 mg daily in two or three divided doses, the range used in most depression trials and echoed by integrative practitioners; effects assessed at 4–6 weeks before any further increase.
  • Standard sleep protocol: 100 mg once daily, taken in the evening. This is the dose used in the two recent older-adult trials and the one with the cleanest tolerability record.
  • Appetite and weight protocol: 750–900 mg daily in three divided doses before meals, as used in the Rome obesity trials; a demanding regimen whose gut side effects cause most of the dropouts.
  • Competing approach — precursor alone: the integrative-practice position, represented by Chris Kresser and reflected in current supplement labelling, holds that unaided 5-HTP produces sufficient central effect at 100–300 mg.
  • Competing approach — precursor plus carbidopa: the neuropharmacology position, argued by Turner and colleagues and popularised by researchers such as van Praag, adds a peripheral decarboxylase inhibitor to push more of the dose brainward. Prescription-only.
  • Time of day: evening dosing suits sleep and mood use and matches melatonin production; daytime split dosing suits appetite control, where the target is pre-meal satiety.
  • Half-life and dose splitting: with a plasma half-life near 2 hours, single daily doses above 100 mg produce a sharp peak and trough; splitting or using sustained-release smooths exposure and is standard above 200 mg.
  • Genetic considerations: MTHFR (the gene for a folate-processing enzyme) and COMT (the gene for a dopamine- and adrenaline-degrading enzyme) variants are widely invoked in commercial protocols, but no pharmacogenetic data support dose adjustment for 5-HTP on any variant.
  • Sex-based differences: no trial has reported sex-stratified dosing or efficacy. The appetite trials enrolled women almost exclusively, so the 750–900 mg range is best evidenced in women.
  • Age-related considerations: adults in their sixties and beyond showed sleep and cognitive effects at 100 mg. The trial record in this group covers a 50 mg start and a 100 mg ceiling, against polypharmacy and fall risk.
  • Baseline biomarkers: low baseline sleep quality, high baseline hunger scores or high baseline depressive symptoms all predict a larger measurable change; those already near optimal showed none.
  • Pre-existing conditions: type 2 diabetes was associated with reduced baseline tryptophan availability and clear response; gut disorders reduce tolerated dose; psychiatric and neuroendocrine conditions rule the intervention out entirely.

Discontinuation & Cycling

  • Not a lifelong intervention: no trial has run beyond 12 months, and the longest controlled exposures are 12 weeks. Use is best framed as a defined course tied to a measurable target rather than indefinite intake.
  • No withdrawal syndrome: unlike serotonergic antidepressants, 5-HTP has produced no documented discontinuation syndrome. Sleep and appetite effects fade within days, matching its short half-life.
  • Tapering rarely needed: abrupt cessation is well tolerated at doses up to 300 mg. Halving the dose for a week before stopping is the usual precaution above that, mainly to observe whether the target symptom returns.
  • Cycling has no efficacy rationale: no tolerance has been demonstrated. Cycling is nonetheless used pragmatically — commonly five days on, two off, or eight weeks on followed by four off — to limit cumulative peripheral serotonin exposure.
  • Defined reassessment checkpoints: if the target outcome has not shifted by 6–8 weeks at an adequate dose, continued use has no evidential support.

Sourcing and Quality

  • Standardised extract, not raw seed: commercial products are seed extracts standardised to 98–99% 5-HTP. Raw or low-standardisation powders carry variable alkaloid content and no reliable dose.
  • Certificate of analysis covering peak X: lot-specific documentation showing impurity screening matters because the only credible safety signal against this compound traces to contaminated material rather than 5-HTP itself.
  • Third-party certification: the relevant marks are USP Verified, NSF Certified for Sport and Informed Choice, alongside good manufacturing practice (GMP, the regulated production standard) certification of the finishing facility.
  • Reputable suppliers: ConsumerLab’s testing has identified passing products across brands including Natrol, Natural Factors, Finest Nutrition and BioScience Nutrition; note that ConsumerLab sells access to those verdicts.
  • Fermentation-derived alternatives: engineered bacterial production of 5-HTP now exists at commercial scale and sidesteps both wild-harvest pressure and plant contaminants, though it is not plant-derived and is labelled differently.
  • Sustainability: the entire world supply comes from wild-harvested West African seed, with Ghana alone exporting over 5,500 tonnes in nine years and destructive cutting of plants during harvest. Ethical sourcing is a genuine constraint, not a marketing claim.

Practical Considerations

  • Time to effect: appetite and satiety changes appear within days at high doses; sleep changes within one to two weeks; mood changes take 4–6 weeks, matching the timeline of conventional serotonergic treatment.
  • Common pitfall — stacking serotonergic products: the frequent error is adding 5-HTP to an existing antidepressant, St John’s wort or tryptophan product without recognising the additive load.
  • Common pitfall — dosing at the wrong end of the range: the 750–900 mg appetite doses get imported into sleep or mood use, producing avoidable nausea; the 50–100 mg sleep doses get used for appetite, producing nothing.
  • Common pitfall — taking it at lights-out: a dose immediately before bed drives the compressed-deep-sleep-then-wake pattern rather than the intended smooth night.
  • Regulatory status: sold as a dietary supplement in the United States under the Dietary Supplement Health and Education Act, meaning no pre-market efficacy or purity review. Regulated as a medicine in Canada and restricted in several European markets.
  • Cost and accessibility: inexpensive and widely available at roughly USD 8–20 monthly. Neither is a barrier, though insurers reimburse generic serotonergic drugs and not supplements — a structural tilt that also steers research funding towards patentable agents.

Interaction with Foundational Habits

  • Sleep: direct and bidirectional. 5-HTP feeds melatonin synthesis, which is the intended mechanism for sleep use, but the same serotonergic push alters sleep staging and can fragment the night. Practical handling: dosing 60–90 minutes before bed rather than at lights-out, with a dose reduction if vivid dreaming or a three-hour wake-up appears.
  • Nutrition: potentiating and competitive at once. Carbohydrate-containing meals raise tryptophan uptake and add to the serotonergic effect, while high-protein meals compete less with 5-HTP than with tryptophan. Taking it with food blunts nausea; separating it from high-dose vitamin B6, which accelerates peripheral conversion, limits gut effects.
  • Exercise: indirect and mildly additive. Endurance exercise raises brain tryptophan uptake by consuming competing branched-chain amino acids, so serotonergic tone rises on both routes. No evidence of blunted hypertrophy or adaptation; dosing before intense training is the point at which drowsiness, where it occurs, becomes limiting.
  • Stress management: indirect. Serotonergic tone participates in stress reactivity, and a single oral dose measurably raises cortisol in neuroendocrine challenge testing (Schruers et al., 2002), though no trial has tested whether daily use alters the stress response. It overlaps with, rather than replaces, behavioural stress work.

Monitoring Protocol & Defining Success

Before starting, a short baseline panel makes later attribution possible: a complete blood count with differential to fix the eosinophil count, a comprehensive metabolic panel covering liver enzymes and kidney function, thyroid-stimulating hormone to exclude a thyroid cause of the same symptoms, and a 24-hour urinary 5-HIAA if there is any suspicion of a serotonin-producing tumour. Alongside the labs, the target symptom is recorded quantitatively — a validated sleep score, a mood score, weight and waist circumference, or a hunger rating — because the effect sizes here are modest and undetectable by impression alone. The blood count and the symptom scores are repeated at 4 weeks and 12 weeks, then every 6 months if use continues. Any new muscle pain, rash or swelling warrants an immediate blood count rather than a scheduled one.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Absolute eosinophil count < 350 cells/µL Detects the white-cell rise preceding eosinophilia-myalgia syndrome Part of a complete blood count (CBC) with differential; conventional labs flag only above 500 cells/µL, so the number matters more than the flag
24-hour urinary 5-HIAA < 6 mg/24 h at baseline Screens for serotonin-producing tumours before loading the pathway 5-HTP itself raises this marker, so the baseline sample precedes the first dose; bananas, avocado, walnuts and pineapple are excluded for 48 h beforehand
Alanine aminotransferase (ALT) < 25 U/L men, < 20 U/L women Confirms hepatic capacity for amino-acid handling Conventional upper limit runs to 40–55 U/L, well above the functional target; fasting sample preferred, paired with aspartate aminotransferase (AST)
Estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m² Establishes clearance capacity for the compound and its metabolites eGFR estimates kidney filtering rate; a paired cystatin C is used where muscle mass is atypical
Thyroid-stimulating hormone (TSH) 0.5–2.0 mIU/L Excludes a thyroid cause of the low mood, fatigue or weight change being targeted Conventional range extends to 4.5 mIU/L; a morning draw paired with free thyroxine (free T4) is standard
Serum serotonin No established target range exists; the change from the individual’s own baseline is tracked instead Confirms the pathway responded rather than proving benefit A rise over baseline was the marker of response in both recent older-adult trials; platelet-poor plasma handling matters more than the absolute figure
Body weight and waist circumference Waist < 94 cm men, < 80 cm women Quantifies the appetite effect, which is otherwise invisible week to week Measurements are taken fasted, at the same time of day, on the same scale; waist matters more than weight for the metabolic goal

Qualitative markers worth tracking alongside the labs:

  • Sleep onset latency and the number of night wakings, ideally from a wearable rather than recall
  • Vivid or disturbing dreams, the earliest sign the evening dose is too high or too late
  • Morning grogginess persisting past the first hour awake
  • Hunger between meals and the specific pull towards carbohydrate
  • Mood stability across the day rather than peak mood
  • Nausea, loose stools or cramping, the limiting factor for most people
  • Libido and sexual function, given the class-level concern

Emerging Research

  • 5-HTP and creatine for treatment-resistant depression: a Phase 2 trial (NCT05895747, University of Utah, 106 participants, recruiting) pairs 5-HTP with creatine as an add-on to standard antidepressants, with the Hamilton Depression Rating Scale as primary endpoint. The first properly powered mood trial in decades.
  • 5-HTP for allergic asthma in children: a Phase 2 trial (NCT04160910, Indiana University, 20 participants, recruiting) tests whether 5-HTP alters lung function, exploring a serotonin-immune axis wholly outside the compound’s established uses.
  • Pain modulation in healthy volunteers: a crossover trial (NCT06893822, Medical University of Graz, 20 participants) has now reported. Rather than relieving pain, 100 mg daily for 28 days increased the spread of allodynia (pain from a normally painless touch), suggesting serotonergic facilitation of pain signalling (Schlemmer et al., 2026).
  • Spinal cord injury excitability: a Phase 2/3 trial (NCT04000919, 30 participants, suspended) examines 5-HTP and levodopa effects on nervous-system excitability and spasticity, a mechanism with no bearing on supplement use but relevant to dose ceilings.
  • Where the case could weaken: the serotonin-deficiency premise underlying mood use is under active challenge, and the crossover trial above (Schlemmer et al., 2026) is the first modern controlled study reporting an unfavourable result. Both bear on whether precursor loading is coherent.
  • Where the case could strengthen: the two recent older-adult trials (Sutanto et al., 2024; Li et al., 2025) point towards sleep and cognitive endpoints at low doses in exactly the demographic this review addresses, and both were too small to settle anything.
  • Sustainability as a research question: engineered microbial production of 5-HTP is advancing quickly, which would decouple supply from wild West African harvest and remove the contamination pathway (Cunningham et al., 2021).

Conclusion

Griffonia simplicifolia is a West African seed whose only meaningful active ingredient is the direct building block of serotonin. That single fact explains both its appeal and its limits: it pushes one chemical messenger upward, non-selectively, everywhere in the body at once.

The clearest signal is on appetite. Several controlled trials in overweight adults found earlier fullness, less carbohydrate eaten and some weight lost, though at daily amounts high enough that stomach upset drives many people to stop. Effects on low mood point the same way across a pooled analysis and a formal review, but the underlying studies are old, small and mostly lacked a dummy comparison. Recent work in adults in their sixties suggests modest gains in sleep and in a cognitive screening score at much lower amounts, while a recent pain experiment found the opposite of what was hoped for.

The safety record is reassuring at the amounts most people use and unforgiving in one respect: combining this seed extract with any medication that also raises serotonin is the mechanism behind every serious reported harm. A separate concern about contaminated batches rests on a handful of cases and on analytical work funded by parties with a stake in the answer.

For someone tracking outcomes and running a defined course against measured endpoints, the compound is cheap and reversible. What it is not is well studied: most of the trial record predates 2000, and an unpatentable seed extract attracts little of the funding that shapes modern evidence.

Top - Benefits - Risks - Protocol